187 related articles for article (PubMed ID: 38496247)
1. Calculations of the binding free energies of the Comprehensive
Negami T; Terada T
Biophys Physicobiol; 2023; 20(2):e200016. PubMed ID: 38496247
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
3. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs.
Negami T; Araki M; Okuno Y; Terada T
Sci Rep; 2019 Nov; 9(1):16586. PubMed ID: 31719645
[TBL] [Abstract][Full Text] [Related]
4. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
5. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
Vicente J; Stockbridge N; Strauss DG
J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs.
Han S; Han S; Kim KS; Lee HA; Yim DS
Front Pharmacol; 2019; 10():1419. PubMed ID: 31849669
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti-arrhythmic compound.
Chen W; Gan L; Wang Y
Eur J Pharmacol; 2019 Feb; 844():130-138. PubMed ID: 30529471
[TBL] [Abstract][Full Text] [Related]
8. Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment.
Rotordam MG; Obergrussberger A; Brinkwirth N; Takasuna K; Becker N; Horváth A; Goetze TA; Rapedius M; Furukawa H; Hasegawa Y; Oka T; Fertig N; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2021; 112():107125. PubMed ID: 34500078
[TBL] [Abstract][Full Text] [Related]
9. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for
Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z
Front Physiol; 2017; 8():917. PubMed ID: 29209226
[TBL] [Abstract][Full Text] [Related]
10. A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Colatsky T
J Pharmacol Toxicol Methods; 2016; 81():233-9. PubMed ID: 27178106
[TBL] [Abstract][Full Text] [Related]
11. The grapefruit polyphenol naringenin inhibits multiple cardiac ion channels.
Sanson C; Boukaiba R; Houtmann S; Maizières MA; Fouconnier S; Partiseti M; Bohme GA
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):735-740. PubMed ID: 35412073
[TBL] [Abstract][Full Text] [Related]
12. Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity.
Sheng J; Tran PN; Li Z; Dutta S; Chang K; Colatsky T; Wu WW
J Pharmacol Toxicol Methods; 2017; 88(Pt 2):109-122. PubMed ID: 28830713
[TBL] [Abstract][Full Text] [Related]
13. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
14. Blinded
Zhou X; Qu Y; Passini E; Bueno-Orovio A; Liu Y; Vargas HM; Rodriguez B
Front Pharmacol; 2019; 10():1643. PubMed ID: 32082155
[TBL] [Abstract][Full Text] [Related]
15. Introduction to
Park JS; Jeon JY; Yang JH; Kim MG
Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576
[TBL] [Abstract][Full Text] [Related]
16. Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.
Brinkwirth N; Takasuna K; Doi M; Becker N; Obergrussberger A; Friis S; Furukawa H; Hasegawa Y; Oka T; Ohtsuki A; Fertig N; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2020 Sep; 105():106884. PubMed ID: 32565325
[TBL] [Abstract][Full Text] [Related]
17. Measuring kinetics and potency of hERG block for CiPA.
Windley MJ; Abi-Gerges N; Fermini B; Hancox JC; Vandenberg JI; Hill AP
J Pharmacol Toxicol Methods; 2017 Sep; 87():99-107. PubMed ID: 28192183
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Orvos P; Kohajda Z; Szlovák J; Gazdag P; Árpádffy-Lovas T; Tóth D; Geramipour A; Tálosi L; Jost N; Varró A; Virág L
Toxicol Sci; 2019 Apr; 168(2):365-380. PubMed ID: 30561737
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Luo F; Gu J; Chen L; Xu X
Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
